Dan Ives, Wedbush Securities global head of technology research, joins CNBC's 'Squawk on the Street' to discuss outlooks on ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

With Elon Musk playing a prominent role in the Trump administration, many Tesla drivers are no longer happy about supporting ...

Despite the recent rash of tech stock sell-offs, the analysts at Wedbush believe this is a short-term phenomenon, and the ...

Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research ...

Market fears over tariffs and growth have hit tech stocks, but Wedbush sees the dip as a buying opportunity for long-term investors ...

U.S. President Donald Trump has stirred controversy by purchasing a Tesla vehicle in a show of support for Elon Musk.

Elon Musk’s role in the Trump administration is complicating his business ventures, as the tech billionaire pushes forward with efforts to slash the federal government and budget in the face of ...

Tesla’s stock began rising from the opening Tuesday after Trump posted overnight on his Truth Social platform that Musk was “putting it on the line” to help the country. Trump claimed in the post that ...

Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Wedbush in a note issued to investors on Monday,RTT News reports. They presently have ...